Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Molnupiravir works by interfering with the replication of virus. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.
Product Name : Molnupiravir-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2021
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide
Details : Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
